Use of visual inspection with acetic acid, Pap smear, or high-risk human papillomavirus testing in women living with HIV/AIDS for posttreatment cervical cancer screening: same tests, different priorities.

AIDS

aAcademic Model Providing Access to Healthcare (AMPATH) Partnership bDepartment of Reproductive Health, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya cDepartment of Biostatistics, Center for Statistical Science, Brown University School of Public Health, Providence, Rhode Island, USA dDepartment of Obstetrics & Gynaecology, University of Toronto, Toronto, Ontario, Canada eDepartment of Pathology, Brown University, Providence, Rhode Island, USA fDepartment of Pathology, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya gDepartment of Obstetrics and Gynecology, The Miriam Hospital, Brown University, Providence, Rhode Island hDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Published: January 2017

Objectives: Few studies have addressed optimal follow-up for HIV-infected women after cervical treatment. This study aimed to compare performance of three available tests to detect posttreatment cervical disease in HIV-infected women in Kenya.

Design: This is a prospective cohort study.

Methods: At least 6 months following cryotherapy, 517 HIV-infected women were evaluated concurrently with visual inspection with acetic acid (VIA), papanicolaou (Pap) smear, and high-risk human papillomavirus (HR-HPV) testing. Women positive by any test (≥low-grade squamous intraepithelial lesion for Pap) were scheduled for colposcopy and biopsy. Among 248 with histological confirmation [and 174 assumed to be truly negative for cervical intraepithelial neoplasia (CIN)2+ after testing negative by all three tests], the ability of each test alone, or in combination, to detect CIN2+ was calculated to determine their utility in posttreatment follow-up.

Results: The median age of women was 35 years, 68% were WHO stage 1-2, with a median CD4 cell count of 410 cells/μl, and 87% were on combination antiretroviral therapy. At a median of 6.3 months posttreatment, 64% had an abnormal screen by VIA, Pap, and/or HR-HPV. Among women with histological confirmation, 72 (30%) had persistent/recurrent CIN2+. As single tests, Pap correctly classified the most cases (83%) and had the highest specificity [91% (88 and 95%); sensitivity 44% (35 and 53%)], whereas HR-HPV had the highest sensitivity [85% (75 and 96%); specificity 54% (49 and 58%)]. VIA was not sensitive [27% (18 and 36%)] for the detection of posttreatment CIN2+ [specificity 82% (79 and 86%)].

Conclusion: With the goal to minimize the number of false negatives (e.g. not miss CIN2+ posttreatment) in this population that is high-risk due to both prior cervical disease and HIV infection, HR-HPV-based algorithms are recommended.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420497PMC
http://dx.doi.org/10.1097/QAD.0000000000001327DOI Listing

Publication Analysis

Top Keywords

hiv-infected women
12
visual inspection
8
inspection acetic
8
acetic acid
8
pap smear
8
smear high-risk
8
high-risk human
8
human papillomavirus
8
testing women
8
posttreatment cervical
8

Similar Publications

Background: Antiretroviral drugs are essential for preventing mother-to-child transmission (MTCT) of HIV in HIV-infected pregnant women. However, ART treatment for HIV-infected pregnant women with multidrug resistance remains a major challenge. Effective and safe ART regimens for preventing MTCT should be tailored to this special population.

View Article and Find Full Text PDF

Aims: In people living with human immune deficiency (PLHIV), the rates of human papillomavirus (HPV) infection, mixed types, and high-risk (HR) strains increase, while the virus clearance is prevented. Here, we report HPV genotyping in PLHIVs from Iran and the Middle East region for the first time.

Methods: HPV genotyping in referring individuals from different provinces to our laboratory was evaluated over 2023-2024.

View Article and Find Full Text PDF

Eight years after WHO adopted a resolution to eliminate hepatitis B by the year 2030, the disease remains a global public health concern, with vertical transmission of HBV being a major obstacle to this goal. Our study aimed to determine the HBV infection status of pregnant women in South Africa at a national level to evaluate the risk of vertical transmission and provide evidence for public health decision-making. We conducted HBsAg testing on 1,942 HIV-uninfected and 2,312 HIV-infected pregnant women from South Africa's public health sector in 2017, followed by HBeAg testing on HBsAg-positive samples.

View Article and Find Full Text PDF

[Incidence and risk factors of anemia among newly reported HIV/AIDS patients in Jiangsu Province in 2021].

Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi

December 2024

School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 210000, China.

Objective: To investigate the incidence of anemia and evaluate the immune status among newly reported HIV/AIDS patients in Jiangsu Province in 2021, and to identify the risk factors of anemia among patients living with HIV infections.

Methods: Newly reported HIV/AIDS patients in Jiangsu Province from January 1 to December 31, 2021 that were registered in China's National AIDS Comprehensive Control Information Management System were enrolled. Subjects' fresh whole blood samples were collected, and hemoglobin levels, CD4 and CD8 cell counts and HIV viral loads were measured.

View Article and Find Full Text PDF

Pneumocystis Jirovecii Pneumonia in Two Immunosuppressed Non-HIV Infected Patients: A Clinical and Therapeutic Analysis.

Infect Drug Resist

January 2025

Department of Clinical Medicine, School of Medicine, Qinghai University, Xining, People's Republic of China.

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection that often occurs secondary to human immunodeficiency virus (HIV) infection. However, for non-HIV immunocompromised patients, such as those undergoing novel immunosuppressive treatments to manage malignancies, organ transplants, or connective tissue diseases, PJP is emerging as an increasing threat. The clinical manifestations of PJP in HIV-infected and non-HIV-infected patients differ significantly.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!